Elevra Lithium Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 11, 2026, reports on a corporate development for Elevra Lithium Limited (ASX:ELV; NASDAQ:ELVR), a North American lithium producer with assets in Canada, the United States, Ghana, and Western Australia. The filing summarizes an ASX announcement dated February 10, 2026, regarding a strategic partnership.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margins, debt, or liquidity figures for Elevra Lithium Ltd. The document focuses exclusively on a commercial agreement. However, it notes that Mangrove Lithium recently secured an US$85 million financing round led by Canada Growth Fund.
Material Changes and Commercial Developments
Elevra has signed a non-binding Memorandum of Understanding (MoU) with Mangrove Lithium to supply spodumene concentrate from its North American Lithium (NAL) project. Key terms include:
- Volume: Up to 144,000 tonnes per year, ramping up by 2030 (approx. 46% of estimated sales volumes).
- Duration: Initial period of five years, commencing in 2028.
- Pricing: Market-related prices with a floor and ceiling to support positive cash flow across pricing cycles.
- Conditions: A binding definitive agreement is contingent on Mangrove making a final investment decision prior to June 2027.
Outlook, Risks, and Management Commentary
Management views this MoU as a significant commercial milestone that strengthens Elevra's position and supports Canada's critical minerals strategy. CEO Lucas Dow highlighted the potential for improved cost efficiency and reinforced competitiveness by supplying a local partner. Strategic benefits include reduced freight costs, a pricing framework that underpins cash flow, and a potential long-term offtake customer for the NAL Brownfield Expansion.
Risks and Contingencies:
- The agreement is currently non-binding; a definitive contract is not guaranteed.
- Execution depends on Mangrove's final investment decision by June 2027.
- Test work on NAL spodumene at Mangrove's pilot plant is ongoing, with results expected in Q3 CY26.
Investor Verification Checklist
- Confirm the status of Mangrove Lithium's final investment decision deadline (June 2027).
- Monitor the results of the NAL spodumene test work at Mangrove's pilot plant (expected Q3 CY26).
- Verify the terms of the definitive agreement once signed, specifically the floor and ceiling price mechanisms.
- Assess the impact of the proposed 2028 commencement date on Elevra's near-term cash flow projections.